• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA clears femtosecond laser platform

Article

The FDA has cleared a new femtosecond laser platform (Femto LDV Z Models, Ziemer Ophthalmic Systems). The platform has been released globally.

Silver Spring, MD-The FDA has cleared a new femtosecond laser platform (Femto LDV Z Models, Ziemer Ophthalmic Systems AG). The platform has been released globally.

“We are looking forward to presenting the products and their unique features to the U.S. audience,” said Graham Hodge, managing director for Ziemer USA Inc. All models are now available for sale in the United States.

The three models in the product line (Z2, Z4, and Z6) are designed to perform a broad variety of procedures in ocular surgery. A practice can start with a lower-level model and upgrade on-site by adding modules as its needs change.

The highest-level model (Z6) is cleared for the creation of corneal incisions in patients undergoing LASIK surgery, tunnel creation for the implantation of intra-corneal rings, and pocket creation for the implantation of corneal implants. This model also can perform lamellar and penetrating keratoplasties or other treatments requiring lamellar resection of the cornea at varying depths.

The mid-level model (Z4) has fewer features, whereas the entry-level model (Z2) is designed to meet everyday LASIK needs.

For more information, visit www.femtoldv.com/z-models.htmlor call 866/708-4490.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.